Low Level Laser Effects On Pain to Palpation and Electromyographic Activity in TMD Patients: A Double-Blind, Randomized, Placebo-Controlled Study

CRANIO® ◽  
2010 ◽  
Vol 28 (2) ◽  
pp. 84-91 ◽  
Author(s):  
Giovana Cherubini Venezian ◽  
Marco Antônio Moreira Rodrigues da Silva ◽  
Rafaela Galli Mazzetto ◽  
Marcelo Oliveira Mazzetto
VASA ◽  
2004 ◽  
Vol 33 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Al-Awami ◽  
Schillinger ◽  
Maca ◽  
Pollanz ◽  
Minar

Background: We recently performed a pilot study which suggested that clinical and thermographic improvements occurred in patients with primary and secondary Raynaud’s phenomenon (RP) following treatment with low level laser irradiation (LLLI). In view of these findings, we have proceeded with a double blind, placebo-controlled study. Methods: Forty seven patients suffering from primary or secondary RP were randomly assigned in a double-blind manner to receive either 10 sessions of distant LLLI (16 f, 8 m, median age 45 years) or placebo irradiation (21 f, 2 m, median age 46 years) during winter months. The attack frequency of RP was measured by a diary count; its severity was assessed by means of visual analogue scale. Response to cold challenge test before and after LLL or placebo treatment was assessed by infrared thermography. Result: Overall a significant reduction of the frequency as well as the severity of RP in patients with either LLLI (frequency p < 0.0001, severity p < 0.0001) or placebo treatment (frequency p < 0.0001, severity p = 0.02) was found, but patients in the LLLI group exhibited a statistically more significant improvement of the frequency at 6 weeks p = 0.007 and 3 months p = 0.02 and the severity p = 0.02, p = 0.04 of RP. Thermographic response to cold challenge improved only in patients treated with LLL but not in those treated with placebo. Conclusion: LLLI significantly lowers the frequency and severity of Raynaud’s attacks in patients with primary and secondary RP. Since this therapeutic modality is a safe, and non-invasive treatment, it might be considered as an alternative to existing therapeutic regimes.


2016 ◽  
Vol 31 (6) ◽  
pp. 1231-1236 ◽  
Author(s):  
Francesca Amadori ◽  
Elena Bardellini ◽  
Giulio Conti ◽  
Nicola Pedrini ◽  
Richard Fabian Schumacher ◽  
...  

LASER THERAPY ◽  
2004 ◽  
Vol 14 (0_Pilot_Issue_2) ◽  
pp. 0_79-0_84
Author(s):  
Mimmi Lögdberg-Andersson ◽  
Sture Mützell ◽  
Åke Hazel

2016 ◽  
Vol 31 (3) ◽  
pp. 511-521 ◽  
Author(s):  
Alessandro Moura Zagatto ◽  
Solange de Paula Ramos ◽  
Fábio Yuzo Nakamura ◽  
Fábio Santos de Lira ◽  
Rodrigo Álvaro Brandão Lopes-Martins ◽  
...  

VASA ◽  
2002 ◽  
Vol 31 (2) ◽  
pp. 91-94 ◽  
Author(s):  
Hirschl ◽  
Katzenschlager ◽  
Ammer ◽  
Melnizky ◽  
Rathkolb ◽  
...  

Background: No causal treatment of primary Raynaud’s phenomenon is available due to its unclear aetiology. Low level laser therapy (LLLT) is applied in a multitude of medical conditions often without sufficient evidence of efficacy and established mechanisms. To asses the effect of this therapy in patients with primary Raynaud’s phenomenon a randomised, double blind, placebo controlled cross over study was designed. Patients and methods: Absolute and relative frequency and intensity of vasospastic attacks during three weeks of either LLLT or placebo therapy and results of infrared thermography before onset and at the end of both therapy sequences were evaluated in 15 patients with primary Raynaud’s phenomenon. Results: Frequency of Raynaud’s attacks was not significantly affected by low level laser therapy. Compared to placebo a significantly lower intensity of attacks during laser irradiation was observed, but no transfer effect occurred. Additionally the mean temperature gradient after cold exposure was reduced after laser irradiation, while the number of fingers showing prolonged rewarming was unaffected. Conclusion: Though further studies are necessary to confirm these results we could demonstrate for the first time in a double blind placebo controlled clinical trial that low laser therapy is a potential candidate for an effective therapy of Raynaud`s phenomenon, although effects seem to be of short duration.


Sign in / Sign up

Export Citation Format

Share Document